Modulating metabolism in MS

Johns Hopkins University researchers showed in Science Tecfidera dimethyl fumarate blocks aerobic glycolysis by inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH), shedding light on how the multiple sclerosis drug suppresses immune activation and suggesting metabolism as a target in other autoimmune diseases.

While Tecfidera was originally developed by Biogen Inc. (NASDAQ:BIIB) as a neuroprotectant, its immunosuppressant activity led to the drug’s use as a psoriasis and MS therapy, even though its immune-suppressing MOA was not completely understood...